Actively Recruiting
Efficacy of Platinum-based Chemotherapy Plus Immune Checkpoint Inhibitors for EGFR/ALK/ROS1 Mutant Lung Cancer
Led by Hunan Province Tumor Hospital · Updated on 2024-06-07
760
Participants Needed
1
Research Sites
288 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
The investigators want to evaluate the Efficay and Safety of Platinum-based Chemotherapy with or without immune checkpoint inhibitors for EGFR/ALK/ROS1 Positive NSCLC who Failed from First-Line Standard Treatment.
CONDITIONS
Official Title
Efficacy of Platinum-based Chemotherapy Plus Immune Checkpoint Inhibitors for EGFR/ALK/ROS1 Mutant Lung Cancer
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Understand the trial requirements and provide signed informed consent
- Age 18 years or older
- Confirmed Stage IV non-small cell lung cancer
- EGFR, ALK, or ROS1-sensitive mutations confirmed by an accredited lab, with progression after first-line therapy
- Eastern Cooperative Oncology Group (ECOG) performance status 0-1
- Predicted survival of at least 12 weeks
- Adequate bone marrow and organ function
- Presence of measurable tumors according to RECIST 1.1 criteria
You will not qualify if you...
- Active or untreated central nervous system metastases
- Other cancers within 5 years before randomization except those with low risk of spread or death treated curatively
- Pregnant or breastfeeding women
- History of autoimmune disease
- History or presence of certain lung inflammations or pneumonitis except radiation-related fibrosis
- Positive HIV test
- Active hepatitis B or C infection
- Severe infection within 4 weeks before randomization
- Significant heart disease
- Any condition preventing understanding or following study procedures
- Prior treatment with CD137 agonists or immune checkpoint inhibitors such as anti-PD-1 or anti-PD-L1 therapies
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
Hunan Cancer Hospital
Changsha, Hunan, China, 410013
Actively Recruiting
Research Team
Y
Yongchang Zhang, MD
CONTACT
N
Nong Yang, MD
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
NON_RANDOMIZED
Model
PARALLEL
Primary Purpose
TREATMENT
Number of Arms
3
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here